NCT00406367 - IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm | Biotech Hunter

Enrollment

109

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

April 30, 2008

Study Completion Date

July 31, 2009

Conditions

Blepharospasm

Interventions

DRUG

incobotulinumtoxinA (Xeomin)

"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, up to 50 Units per eye; Mode of administration: intramuscular injection"

DRUG

Placebo

Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium chloride (NaCl), placebo volume corresponding to up to 50 Units per eye; Mode of administration: intramuscular injection

Trial Locations (2)

77030

Baylor College of Medicine, Houston

B3J 3T1

David King, MD - Private Practice, Halifax